Blood is defined as entire human blood that has been obtained from a donor and processed for transfusion or further production. Blood component refers to a therapeutic component of human blood, including its red, white, platelet, and plasma cells. The blood and blood components market consist of sales of blood and blood component. The market involves the collection of donor's blood and segregating it into required components for the purpose of therapy. The main types of products in blood and blood components are whole blood and blood components. Human blood from a typical blood donation is known as whole blood. It is utilized in the treatment of excessive bleeding, exchange transfusions, and self-donation of blood. The different blood components include red blood cells, platelets, plasma, and white blood cells and are used in anemia, trauma and surgery, cancer treatment, and bleeding disorders. The several end-users involved are hospitals, ambulatory surgical centres, and others. The blood and blood components market research report is one of a series of new reports from The Business Research Company that provides blood and blood components market statistics, including blood and blood components industry global market size, regional shares, competitors with a blood and blood components market share, detailed blood and blood components market segments, market trends and opportunities, and any further data you may need to thrive in the blood and blood components industry. This blood and blood components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global blood and blood components market size will grow from $37.49 billion in 2022 to $39.21 billion in 2023 at a compound annual growth rate (CAGR) of 4.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global blood and blood components market size is expected to grow to $47.53 billion in 2027 at a CAGR of 4.9%. The blood and blood components market is being driven by increasing incidence of trauma and road accidents. Sometimes, because of traumas such as hemorrhage, the volume of blood is reduced to a very low level and cannot be replaced fast enough by the body. Also, road accidents cause excessive blood loss from the body that has to be restored immediately. At times, the blood itself lacks a few components as in the case of hemophilia. All these conditions demand transfusion of blood and blood components into the patient's body. The growing prevalence of diseases and increasing numbers of road accidents and traumas are increasing the demand for blood and thus driving the market. According to a report by Centres for Disease Control and Prevention, Hemophilia A affects one out of every 5,000 male babies born. Every year, about 400 newborns are born with haemophilia. Also, according to the Arizona Department of Health Services, in 2021, trauma related deaths increased by 19% as compared to 2020. Falls accounted for most deaths and injuries. The blood and blood components market is restrained by the growing risk of developing or transferring an infection while the blood is transmitted to the patients. The growing possibilities of developing any transfusion transmitted infection (TTI) is imposing a restriction on the growth of the market. The fear of transfusion of diseases from the donor to the recipient, forces many customers to avoid using donated blood, thus hampering the growth of the blood and blood components market. The most common viral agents that can be transmitted through blood transfusion are Human Immunodeficiency Virus (HIV), hepatitis viruses, West Nile Virus (WNV), Human T-cell Lymphotrophic Viruses (HTLVs). The most prominent trend that has been witnessed in the blood and blood components market is the growing number of collaborations between the players involved in the market. Companies are adopting partnerships and collaborations in order to expand their reach, increase customer base and generate awareness in the market. For example, the American Red Cross collaborated with HealthStream with an aim of introducing new program for healthcare organizations. Similarly, the BloodCenter of Wisconsin collaborated with SysLogic Inc., to study how the RFID technology can be used to enhance safety of the patient while collecting and transfusing blood products. The blood and blood components market in European Union is governed by Directive 2002/98/EC of the EU regulations. The regulatory body engages itself in providing guidelines and setting standards for quality and safety of collection, testing, processing, storage, and distribution of blood and blood components. These guidelines ensure greater quality and safety of whole blood and its components to prevent transmission of diseases and also highlight necessary measures for their collection and distribution. In October 2022, Pfizer, a US-based pharmaceutical company, acquired Global Blood Therapeutics for an undisclosed amount. The acquisition will strengthen Pfizer's capabilities in treating sickle cell disease while preserving the company's 30-year legacy.Global Blood Therapeutics is a US-based developer of treatments related to blood diseases, especially sickle cell disease.  Major players in the blood and blood components market are the American Red Cross, Australian Red Cross Blood Service, Abbott Laboratories, Blood Centres of America, Becton, Dickinson & Co., German Red Cross, Nipro Medical Corporation, American Association of Blood Banks, AVIS National, and National Blood Authority Australia. North America was the largest region in the blood and blood components market in 2022. Western Europe was the second largest region in the global blood and blood components market. The regions covered in the global blood and blood components market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the blood and blood components market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The blood and blood components market consist of sales of red cells, platelets, plasms, cryoprecipitated AHF, and granulocytes. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global blood and blood components market is segmented - 1) By Product: Whole Blood, Blood Components 2) By End-Users: Hospitals, Ambulatory Surgical Centers, Other End-Users 3) By Application: Anemia, Trauma & Surgery, Cancer Treatment, Bleeding Disorders 4) By Blood Components: Red Blood Cells, Platelets, Plasma, White Blood Cells

Convalescent plasma is plasma that has been collected from people who have recovered or are convalescing and contains antibodies against the infection-causing microorganism.It is used for the treatment of patients infected by the respective pathogen. The main antibody types of convalescent plasma therapy are IgM, IgG, and IgA. Immunoglobulin A (IgA) is an antibody that is essential for mucous membrane immunological activity. The different applications include prophylaxis, and treatment and are used in various sectors such as hospitals and clinics, laboratories, and research institutes. The convalescent plasma therapy market research report is one of a series of new reports from The Business Research Company that provides convalescent plasma therapy market statistics, including convalescent plasma therapy industry global market size, regional shares, competitors with a convalescent plasma therapy market share, detailed convalescent plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the convalescent plasma therapy industry. This convalescent plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global convalescent plasma therapy market size will grow from $0.04 billion in 2022 to $0.05 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global convalescent plasma therapy market size is expected to grow from $0.07 billion in 2027 at a CAGR of 12.0%. Higher efficacy and safety evaluated during the trials conducted for CPT in COVID-19 patients can drive the market growth during the forecast period. Convalescent plasma transfusion has been of interest in the historical period for the treatment of other infectious disease outbreaks such as SARS-1, Middle East Respiratory Syndrome (MERS), and 2009 H1N1. In June 2020, results of a study conducted by the Houston Methodist hospital, which aimed at evaluating safety and efficacy of COVID-19 convalescent plasma therapy, stated that the convalescent plasma therapy is safe with no adverse events reported and is efficient with 76% recovery rate. In May 2020, a study published in the Journal of Medical Virology stated that with convalescent plasma therapy, the mortality rate may be reduced in critically ill patients, beneficial effects on clinical symptoms will be observed, and an increase in neutralizing antibody titers and disappearance of SARS-CoV-2 RNA will be observed. The safety and efficacy of the convalescent plasma therapy in COVID-19 patients will boost market growth. The availability of scant evidence regarding the safety and efficacy of convalescent plasma therapy led to strict guidelines by government authorities. Different government authorities like the US FDA, CDSCO of India, and others have approved COVID-19 convalescent plasma for investigational use only and not for prescribed indication. In May 2020, FDA released guidelines for COVID-19 convalescent plasma therapy, which stated that the administration of COVID-19 convalescent plasma must be under the investigational new drug application (IND) for clinical trials, expanded access, and single-patient emergency only. Even for a single patient emergency, an eIND must be filed with FDA for the use of convalescent plasma therapy, provided, the health care provider must determine that the probable risk from the investigational drug is not greater than the probable risk from the disease or condition. COVID-19 convalescent plasma should be obtained from an FDA-registered blood establishment that follows the donor eligibility criteria and donor qualifications. The manufacturing process and shelf life should be the same as that of other similar plasma products. These strict guidelines framed by authorities are expected to limit the market growth. The development of antibody-based immunotherapy as a potential therapeutic intervention for COVID-19 shows opportunities for the convalescent plasma therapy market. Convalescent plasma therapy utilizes the antibodies produced against coronavirus by the donor to improve the immunity of the recipient. Companies are initiating trials, collaborating and investing for antibody-based COVID-19 therapy. In April 2020, GSK entered into a collaboration with Vir Biotechnology and invested $250 million in Vir to support the development of anti-viral antibody-based solutions against novel coronavirus. In April 2020, Biomedical Advanced Research Development Authority (BARDA) partnered with Emergent BioSolutions to fund $14.5 million to support the development of human plasma-derived therapy which is COVID-Human Immune Globulin (COVID-HIG) for treating COVID-19 in severe hospitalized and high-risk patients. In April 2020, global plasma companies like CSL Behring, Takeda Pharmaceutical Company Limited, Biotest, BPL, LFB, and Octapharma collaborated to develop plasma-derived COVID-19 Hyperimmune Therapy. As convalescent plasma therapy utilizes antibodies, the focus over antibody-based COVID-19 therapy is expected to boost the market growth. In March 2020, Grifols, a Spain-based multinational pharmaceutical and chemical manufacturer that develops, produces, and markets innovative solutions under divisions - Bioscience, Diagnostic, Hospital and Bio Supplies, announced its collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies. Under this collaboration, Grifols will collect plasma from FDA-approved plasma collection centres to develop a hyperimmune globulin as a treatment option for COVID-19 patients and will support the convalescent plasma therapy approach by providing inactivated plasma for transfusion using viral inactivation technology (methylene blue). FDA is a federal agency and BARDA is an authority of the United States Department of Health and Human Services that protects public health through the transition of medical products like vaccines, biopharmaceuticals, pharmaceuticals, and others from research to FDA approval for public use. Major players in the convalescent plasma therapy market are Bio Farma, Grifols, Hilton Pharma, Biotest, BPL, LFB, Octapharma, CSL Behring, Takeda Pharmaceutical Company Limited and Orthosera Kft. North America was the largest region in the convalescent plasma therapy market in 2022. Western Europe was the second largest region in the global convalescent plasma therapy market. The regions covered in the global convalescent plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the convalescent plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The convalescent plasma therapy market includes revenue earned by IgD and IgE. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global convalescent plasma therapy market is segmented - 1) By Application: Prophylaxis, Treatment 2) By End-Users: Hospitals & Clinics, Laboratories & Research institutes 3) By Antibody type: IgM, IgG, IgA

Patient blood management is a patient-focused, evidence-based and systematic approach to optimize care of patients, who might need a blood transfusion, by optimizing patients’ blood, minimizing surgical blood loss, and harnessing the patient-specific physiological reserve of anemia thereby reducing the need for allogeneic blood transfusions. The patient blood management market is segmented by product into instruments, accessories, reagents and kits, software. The patient blood management kits are used to manage the patient’s blood. It is also segmented by component into plasma, whole blood, and red blood cells that are used for applications such as hospitals, clinics, and others. The patient blood management market research report is one of a series of new reports from The Business Research Company that provides patient blood management market statistics, including patient blood management industry global market size, regional shares, competitors with a patient blood management market share, detailed patient blood management market segments, market trends and opportunities, and any further data you may need to thrive in the patient blood management industry. This patient blood management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global patient blood management market grew from $12.82 billion in 2022 to $13.83 billion in 2023 at a compound annual growth rate (CAGR) of 7.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The patient blood management market is expected to grow from $17.42 billion in 2027 at a CAGR of 6.0%. The rising number of accidents, trauma cases, and surgical procedures contributed to the growth of the global patient blood management market. According to WHO, 1.35 million people die every year due to road accidents, and low-income and middle-income countries account for 93% of the fatalities occurring in the world due to road accidents. According to the Centers for Disease Control and Prevention, in 2021, the caesarean birth rate was 32.1% of all the births. Increased number of accidents, trauma cases, and surgical procedures resulted in increased demand for blood, and its products are driving the global patient blood management market. The high cost associated with automated systems is expected to limit the growth of the global patient blood management market. Costs associated with an increasing regulatory requirement, infection testing, and hospital administration, which include initial project costs, personnel salaries, costs of equipment, outside resources, and ongoing project costs make automation expensive. According to the Researchgate, in 2022, the expected cost of transfusion of one unit of red cells is US$ 600–$1200. The high economic cost of automation is therefore expected to hamper the global patient blood management market. HEMAsavR is a sterile medical device to capture and transfer blood, which is increasingly being used to collect and salvage blood in surgical procedures and respond quickly to unanticipated blood loss. Clinicians can economically collect sterile, anticoagulated blood without any need for specialized resources. By this, the upfront shed blood collection cost decreases, allogenic transfusions can be avoided with improved outcomes such as decreased patient mortality, low incidence of infections, and reduced risk of multi-organ failure. Major players in the patient blood management market are Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo Corporation, Immucor Inc., B. Braun Melsungen AG, Macopharma, bioMérieux SA, Asahi Kasei Corporation, Kaneka Corporation, and Bio-Rad Laboratories Inc. North America was the largest region in the patient blood management market in 2022. Western Europe was the second largest region in the global patient blood management market report. The regions covered in the global patient blood management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the patient blood management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The patient blood management market includes revenues earned by instruments, blood processing devices, and centrifuges. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global patient blood management market is segmented - 1) By Product: Instruments, Accessories, Reagents And Kits, Softwares 2) By Component: Plasma, Whole Blood, Red Blood Cells 3) By Application: Hospital, Clinic, Other Applications

Plasma therapy refers to a treatment that substitutes missing or inadequate proteins to help people live healthier and more fruitful lives. It introduces antibodies into individuals receiving therapy using blood donated by recovered patients. The main types of plasma therapy are pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin (PRF), and leukocyte-rich fibrin (L-PRF). Pure Platelet-Rich Plasma (P-PRP) or leucocyte-poor PRP goods are activated preparations that lack leucocytes and have a low-density fibrin system. The different applications include orthopedics, arthritis, chronic tendinitis, bone repair and regeneration, dermatology, androgenic alopecia, plastic surgery, dental, cardiac muscle injury, and others and are implemented in various sectors such as hospitals and clinics, laboratories, and research institutes. The plasma therapy market research report is one of a series of new reports from The Business Research Company that provides plasma therapy market statistics, including plasma therapy industry global market size, regional shares, competitors with a plasma therapy market share, detailed plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the plasma therapy industry. This plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global plasma therapy market grew from $0.4 billion in 2022 to $0.44 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The plasma therapy market is expected to grow from $0.69 billion in 2027 at a CAGR of 11.7%. The rising prevalence of osteoarthritis is expected to drive the plasma therapy market during the forecast period. Platelet-rich plasma (PRP), a type of plasma therapy, is considered a safe and efficient treatment for osteoarthritis. Platelet-rich plasma (PRP) is a concentrated autologous blood growth factor that is injected into the joint to provide symptomatic relief by decreasing inflammation and slowing the progression of osteoarthritis. For instance, in July 2020, according to the Centers for Disease Control and Prevention (CDC), around 32.5 million people in the USA will be suffering from osteoarthritis. Some of the most commonly used treatments for osteoarthritis are autologous chondrocyte implantation and scaffold implants. Therefore, an increase in the prevalence of osteoarthritis is expected to drive the plasma therapy market. The high cost of plasma therapy is expected to hinder the market. The major reason contributing to the high cost is due to extraction and storage. Plasmapheresis is the process of separating plasma and blood cells from blood.The cost of plasmapheresis is approximately $5,000 to $10,000 in the United States. Average platelet-rich plasma orthopaedic treatment costs range from $350 to $1,050 for a single sitting, and it may require 2 to 3 settings for the treatment to be effective. The high cost of plasma therapy hinders many patients from accessing the treatment, thereby impacting the market negatively. Convalescent plasma therapy, to treat patients suffering from COVID-19, is a leading trend in the plasma therapy market. Convalescent plasma is the plasma extracted from individuals who have been cured of a particular viral infection, as they have antibodies that protect and make them immune to that particular organism. The convalescent plasma is transfused to the patient who is suffering from the viral infection to neutralise the infection and induce an active immune response to cure the infection. Convalescent plasma therapy is found to be a safe treatment to cure patients infected with the coronavirus. Moreover, this therapy was used to treat other viral infections such as Ebola, Dengue, and SARS-1 but did not give the desired results. In March 2020, Takeda Pharmaceutical Company Limited has initiated a plasma therapy, Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), which is termed TAK-888 for treating COVID-19. The TAK-888 utilises the plasma collected from convalescent donors who have been cured of COVID-19 and is administered to the patient suffering from COVID-19. Major players in the plasma therapy market are Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Arthrex, Inc., Biotest AG, China Biologic Products Holdings, Inc., DePuy Synthes Companies, CSL Limited, Grifols, S.A., Octapharma, and Terumo BCT Inc. North America is the largest region in the Remdesivir market in 2022. The Middle East is expected to be the fastest growing region in the global plasma therapy market during the forecast period. The regions covered in the global plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The plasma therapy market includes revenues earned by entities by replacing missing or deficient proteins and developing better means of managing the disease. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global plasma therapy market is segmented - 1) By Type: Pure PRP, Leukocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF) 2) By Application: Orthopaedics, Arthritis, Chronic Tendinitis, Bone Repair & Regeneration, Dermatology, Androgenic Alopecia, Plastic Surgery, Dental, Cardiac Muscle Injury, Other Applications 3) By End-Users: Hospitals & Clinics, Laboratories: Research Institutes

The mycoplasma testing detects mycoplasma pneumoniae, which causes mycoplasma pneumonia. Mycoplasma pneumonia is a contagious respiratory infection that spreads easily through contact with respiratory fluids. It can cause epidemics. Mycoplasma testing includes a group of tests that measures antibodies in the blood produced in response to a mycoplasma infection and detects the microbe directly through detecting or culturing its genetic material (DNA) in a body sample. The main types of mycoplasma testing technologies include polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), enzymatic methods, and deoxyribonucleic acid (DNA) staining. Polymerase chain reaction (PCR) detects mycoplasma species using primers specific for mycoplasma DNA, usually mycoplasma 16S rRNA genes. Enzyme-linked immunosorbent assay (ELISA) detects the presence of mycoplasma using either antibodies, or labeled probes for the mycoplasma 16S rRNA genes. Enzymatic methods use a sample of the suspected cell culture which converts ADP to ATP using mycoplasmal enzymes. Deoxyribonucleic acid (DNA) staining detects the mycoplasma strain M. hyorhinis by growing a sample of suspected cell cultures with Vero cells, and staining the cells for DNA using a fluorescent dye. The different products in mycoplasma testing include instruments, assay, kits, and reagents. Mycoplasma testing is applied in cell line testing, virus testing, and end- of- production cell testing and is used by pharmaceutical & biotechnology companies, cell banks & laboratories, contract research organizations, academic research institutes. The mycoplasma testing market research report is one of a series of new reports from The Business Research Company that provides mycoplasma testing market statistics, including mycoplasma testing industry global market size, regional shares, competitors with a mycoplasma testing market share, detailed mycoplasma testing market segments, market trends and opportunities, and any further data you may need to thrive in the mycoplasma testing industry. This mycoplasma testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global mycoplasma testing market size grew from $0.81 billion in 2022 to $0.92 billion in 2023 at a compound annual growth rate (CAGR) of 13.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The mycoplasma testing market size is expected to grow to $1.47 billion in 2027 at a CAGR of 12.5%. The prevalence of mycoplasma pneumonia co-infection among patients with COVID-19 is expected to boost the market for mycoplasma testing in the forecast period. The presence of co-infection of M. pneumonia increases the need to test patients with COVID-19, increasing demand for routine diagnostic tests for respiratory pathogens like M. pneumonia. The coinfections in COVID-19 cases has a significant probability of them being caused by Mycoplasma pneuminiae. For instance, according to a 2020 study published in the Archives of Medical Laboratory Sciences, the co-infection due to M. pneumonia varied between 1 and 40.6% depending on the population and diagnostic tests used and the combined prevalence of M. pneumoniae co-infection among patients with COVID-19 was reported by 17%. The lack of skilled/trained molecular biologists is expected to restrain the growth of the market in the forecast period. Mycoplasma testing requires specialized skillsets relating to life sciences, pharmaceuticals, electronics and software. These skillsets are available to a limited number of organizations, most of which are located in the USA and Europe. Lack of trained manpower capable of performing the molecular biology experiments and interpreting the results is a major limitation in the testing and confinement of COVID-19 in developing countries. For the few laboratory experts present in these countries, priority is given to other medical emergencies such as heart attacks and road accidents. This shortage of skilled labor is expected to be a significant deterrent to the growth of the market during the forecast period. Major players operating in the market are undertaking various strategic investments such as the launch of innovative products, research and development advancements, and technological innovations, which are gaining significant popularity in the mycoplasma testing market. Companies are introducing new innovative products to meet the requirements of end-users and expand the consumer base to survive in the competitive business environment. For instance, in July 2020, bioMérieux, a France-based biotechnology company introduced Bio Fire Mycoplasma, an advanced test used for bio-therapeutics including hormones, antibodies, gene, and cell therapies for mycoplasma detection in pharmaceutical products. In January 2020, Charles River Laboratories International, Inc., a USA-based company specializing in a variety of preclinical and clinical laboratory services for the biotechnology, pharmaceuticals, and medical devices industry acquired HemaCare Corporation for approximately $380 million in cash. With the acquisition, Charles River Laboratories International, Inc. expands the scientific capabilities of the company in the high-growth cell therapy sector and HemaCare cellular products improve Charles River Laboratories ability to offer a comprehensive cell therapy solution, including mycoplasma detection. HemaCare Corporation is a USA-based company engaged in the production of human-derived biological products and services for cellular therapy development, drug discovery, and biomedical research. Major players in the mycoplasma testing market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza, PromoCell GmbH, American Type Culture Collection, Charles River Laboratories International Inc., Bionique Testing Laboratories Inc., Biological Industries Israel Beit Haemek Ltd., InvivoGen, Agilent Technologies, Abbott, Roche Diagnostics, Boston Scientific Corporation, Clongen Laboratories LLC, Creative Bioarray, Nelson Laboratories Fairfield Inc., Norgen Biotek Corporation, Biotools B & M Labs S.A, GenBio, GeneCopoeia Inc., Minerva Biolabs GmbH, Mycoplasma Experience, Savyon Diagnostics, ScienCell Research Laboratories Inc., AngioDynamics, AtriCure Inc., CONMED Corporation, Olympus Corporation, Smith & Nephew, and Advanced Cardiac Therapeutics. North America was the largest region in the mycoplasma testing market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the mycoplasma testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mycoplasma Testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The mycoplasma testing market includes revenues earned by entities by PCR detection assay, indirect hoechst stain, and culture isolation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global mycoplasma testing market is segmented - 1) By Product: Instruments, Assay, Kits, and Reagents 2) By Technology: PCR, ELISA, Enzymatic Methods, DNA Staining, Other Technologies 3) By Application: Cell line Testing, Virus Testing, End- of- Production Cell Testing 4) By End User: Pharmaceutical & Biotechnology Companies, Cell Banks & Laboratories, Contract Research Organizations, Academic Research Institutes

The cold plasma is also referred to as non-thermal atmospheric pressure plasma and is used in industries such as plastics and polymers, textiles, electronics, food and agriculture, and medicine. Cold plasma is a reactive gas containing different amounts of ions, electrons, and neutral particles in the air that allows us to generate ozone from oxygen molecules by means of electrical discharges via atmospheric gases. The main types of cold plasma by regime are atmospheric cold plasma and low-pressure cold plasma. Atmospheric cold plasma is an ionized gas with a near room temperature. It is a source of reactive species, neutral particles, electromagnetic fields, and UV radiation that may be controlled. Cold plasma is used on the basis of technology, which includes remote treatment, direct treatment, and electrode contact. These are used for wood healing, blood coagulation, dentistry, cancer treatment, and other medical applications. Cold plasma is also used by end users such as automotive, electronics & semiconductors, food processing & packaging, medical, aerospace, and polymers & plastics. The cold plasma research report is one of a series of new reports from The Business Research Company that provides cold plasma statistics, including cold plasma industry global market size, regional shares, competitors with cold plasma shares, detailed cold plasma segments, market trends and opportunities, and any further data you may need to thrive in the cold plasma industry. This cold plasma research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cold plasma market size grew from $2.35 billion in 2022 to $2.72 billion in 2023 at a compound annual growth rate (CAGR) of 15.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The cold plasma market size is expected to grow to $4.99 billion in 2027 at a CAGR of 16.5%. The increased use of cold plasma technology across various industries is expected to propel the growth of the cold plasma market. Cold plasma technology is becoming more popular in medical and industrial applications such as healthcare devices and diagnostics. Cold plasma therapy is also being promoted as a viable treatment for the continuing COVID-19 outbreak. Cold plasma has the potential to kill bacteria, especially drug-resistant bacteria, preventing further infection and aiding in the treatment of chronic wounds. Cold plasma can help in the hydrophilization process in the textile industry in the treatment of protective clothing and sterile materials to reduce microorganisms. As per the German Federal Statistical Office 2020 report, there are about 83 million people in Germany, of which 16.2 million people are over 67 years of age, and it is projected to reach 21.4 million by 2040. With the increase in the geriatric population, there is also an increase in the diabetic population, which results in chronic wounds such as foot ulcers and thus boosts the overall market. Therefore, the increased use of cold plasma across various industries is driving the growth of the cold plasma market. Technological advancements are a key trend gaining popularity in the cold plasma market. Technological advancement is the advancement in technology. For instance, in June 2021, Nordson Corporation, a US-based developer and manufacturer of dispensing equipment, launched MARCH MegaVIATM Plasma Treatment System for large panels in printed circuit board manufacturing. The new MegaVIATM system delivers greater panel loading by more than 54% with only a 2% increase in footprint and overall dimensions of 1652mm W x 1782mm D x 2326mm H. High process reproducibility and plasma treatment uniformity for PCB panels are provided by the new platform. In July 2020, Grifols, a prominent developer of plasma-derived pharmaceuticals, acquired GC, Pharma Group's plasma fractionation unit and two purification units in Montreal, as well as 11 plasma collection centers in the United States for USD 460 million. This acquisition is aimed at expanding Grifols' plasma collection and fractionation capacity to enable access to plasma-derived medicines worldwide. GC Pharma (GC Pharma), a subsidiary of Green Cross Holdings Corp., provides plasma protein therapeutics and vaccines. Major players in the cold plasma market are Ethicon Inc., Baxter International Inc., 3M Company, Smith & Nephew plc., Nordson Corporation, Plasma Etch Inc., Adtech Plasma Technology Co., P2i Ltd., Relyon Plasma GmbH, Henniker Plasma, Enercon Industries, AcXys Plasma Technologies, Plasmatreat, Europlasma, SOFTAL, and UNIQAIR Technologies. Asia-Pacific was the largest region in the cold plasma market in 2022. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the cold plasma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cold plasma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cold plasma market consists of sales of cold plasma derived from techniques such as corona discharge and plasma jet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cold plasma market is segmented - 1) By Regime: Atmospheric Cold Plasma, Low-Pressure Cold Plasma 2) By Technology: Remote Treatment, Direct Treatment, Electrode Contact 3) By End Use Sector: Automotive, Electronics & Semiconductors, Food Processing & Packaging, Medical, Aerospace, Polymers & Plastics, Other End-User Sector 4) By Application: Wound Healing, Blood Coagulation, Dentistry, Cancer Treatment, Other Medical Applications

The porcine plasma feed refers to a feed ingredient containing highly digestible proteins, amino acids, and other significant amounts of functional bioactive components such as immunoglobulins, transferrin, growth factors, peptides, and other biologically active ingredients used as the mainstay in pigs' diets. The primary purpose of porcine plasma is to be used as a feed additive in pig food to increase average growth and maintain pig nutrition.     The main types of porcine plasma feed are powder, grain, and others. Powder-based porcine plasma feed refers to powder-based feed additives used to enhance performance and health. Powder-based porcine plasma feed is a hygienically obtained and veterinary-approved animal protein that dissolves very easily and has many excellent functional properties. The porcine plasma feed is used for pet food, aquafeed, and other applications, and the end-users include farmers, farming organizations, feed additive companies, and animal feed for pets. The porcine plasma feed market research report is one of a series of new reports from The Business Research Company that provides porcine plasma feed market statistics, including porcine plasma feed industry global market size, regional shares, competitors with a porcine plasma feed market share, detailed porcine plasma feed market segments, market trends and opportunities, and any further data you may need to thrive in the porcine plasma feed industry. This porcine plasma feed market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global porcine plasma feed market size grew from $1.13 billion in 2022 to $1.21 billion in 2023 at a compound annual growth rate (CAGR) of 6.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The porcine plasma feed market size is expected to grow to $1.55 billion in 2027 at a CAGR of 6.5%. Increasing consumer spending on pet food is the major factor driving the porcine plasma feed market growth. The pet food industry has grown considerably in the last few years due to increasing food and feed adulteration cases. Pet food with essential amino acids helps to develop and grow and provides several other vital nutrients to pet animals. The addition of such plasma feed additives to the pet's diet provides them with a more accessible digestive system and an improved immune system and metabolism. For Instance, in August 2021, according to the European pet food industry, the annual value of pet-related products and services in Spain is EUR 19.7 billion ($20.02 billion). Additionally, in September 2021, according to a Wren Kitchens article, a UK-based designer, manufacturer, and retailer of kitchens, one in ten (11%) Americans spend the same amount on their pet food as they do on home food, while 6% of Americans spend more on their pet food than they do on household food. Therefore, increasing consumer spending on pet food is expected to boost demand for porcine plasma feed during the forecast period. Technological innovation is the key trend gaining popularity in the porcine plasma feed market. The market is witnessing the implementation of advanced technological innovations such as spray-dried porcine plasma, an abattoir by-product used in animal nutrition with reported positive effects in livestock. Spray-dried porcine plasma is an ingredient with greater nutritional value, as it provides highly digestible protein with an ideal amino acid profile. This spray-dried animal plasma (AP) is widely used to produce animals' post-weaning diets to improve growth and well-being. Major companies operating in porcine plasma feed are focused on providing such advanced innovation to strengthen their market position. For instance, in February 2021, Diamond V, a US-based manufactures of natural immune-support postbiotic feed additives, experimented with and innovated an old product line into a new product line named Dia-V™, an immune health piglet feed additive used in nursery pig diets. These Dia-V Nursery fermentate feed additives work with the piglet's biology that helps maintain immune strength, digestive tissue integrity, and a healthy microbial balance. In May 2022, Darling Ingredients Inc., a United States-based provider of sustainable natural ingredients, acquired Valley Proteins for an undisclosed amount. With this acquisition, Darling Ingredients Inc is focused on strengthening its business and providing additional low low-carbon intensity feedstocks. Valley Proteins is a United States-based rendering and recycling of animal by-products company that offers animal fats and oils, protein meals, and pet food ingredients. Major players in the porcine plasma feed market are APC Proteins, SARIA A/S GmbH & Co. KG, FASA Group, Lican Food, Puretein Agri LLC, Valley Proteins, Inc., Kraeber & Co Gmbh, Ridley Corporation Limited, West Coast Reduction Ltd., Nutreco, Lihme Protein Solutions, Ekofood, FeedWorks Pty. Ltd., Darling Ingredients Inc., and Engromix. North America was the largest region in the porcine plasma feed market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the porcine plasma feed market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the porcine plasma feed market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The porcine plasma feed market consists of sales of peptides, biologically active components, transferrin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global porcine plasma feed market is segmented - 1) By Type: Powder, Grain, Other Types 2) By Application: Pet Food, Aquafeed, Other Applications 3) By End-User: Farmers, Farming Organizations, Feed Additive Companies, Animal Feed for Pets

Blood transfusion diagnostics are used to conduct tests before the transfusion of blood from donor-recipient such as blood grouping disease screening. The main types of blood transfusion diagnostics are instruments and kits, reagents, and others. The blood transfusion diagnostic kits are used to collect and transfuse blood. The technologies involved in blood transfusion diagnostics are western blot, ELISA, nucleic acid amplification, fluorescence assay, and rapid test that are used for various applications such as blood grouping and disease screening. The end-users involved are hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood transfusion diagnostics market research report is one of a series of new reports from The Business Research Company that provides blood transfusion diagnostics market statistics, including blood transfusion diagnostics industry global market size, regional shares, competitors with a blood transfusion diagnostics market share, detailed blood transfusion diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the blood transfusion diagnostics industry. This blood transfusion diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global blood transfusion diagnostics market grew from $3.65 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The blood transfusion diagnostics market is expected to grow from $5.68 billion in 2027 at a CAGR of 9.3%. Patients undergoing surgical procedures need a blood transfusion to replace the lost blood during the procedure. Blood transfusion diagnostics are used during the procedures to screen the blood before transferring it to the patient and will otherwise increase the incidence of infectious disease. According to an article published in the US National Library of Medicine, National Institutes of Health, approximately 310 million surgeries are being performed each year. This increase in the number of procedures will thereby drive the need for blood transfusion diagnostics. Developing and underdeveloped countries lack adequate blood banks, proper medical equipment for blood transfusion, adequate conditions for the storage of blood, and low supply for the high demand of blood. Hospitals are not equipped with proper amenities that help provide hygienic and safe transfusions. For example, according to research conducted by India Spend, around 1.18 million units of blood were wasted during storage in the form of discoloration, bacterial contamination, and expiry due to outdating. The poor infrastructure hampers the growth of the blood transfusion diagnostic market. The growing demand for advanced diagnostic measures and growing prevalence of infectious diseases associated with pathogens such as bacteria & viruses increase the preference for nucleic acid amplification testing (NAAT/NAT) to increase blood safety, improve efficiency and reduce the turnaround time of the results. NAT is a technique that helps detect a particular nucleic acid, virus, or bacteria that acts as a pathogen in blood, tissue, or urine. NAT is highly sensitive and specific for viral nucleic acids and amplifies the region of targeted viral DNA and detects them earlier than the other traditional methods and narrows the period of infectious diseases. For example, XCRP Diagnostic Inc. and Luminex Corporations entered into a licensing agreement of XCR Diagnostic's Xtreme Chain Reaction Nucleic Acid Amplification Technology. In this deal, Luminex got the exclusive rights to use the XCR Diagnostic's NAAT technology for their future molecular diagnostic portfolio. The blood transfusion diagnostics market is highly regulated by governing bodies such as USFDA (the USA Food and Drug Administration), and the Medicines and Healthcare products Agency (MHRA). For instance, the manufacturers and service providers in the USA must comply with the Center for Biologics Evaluation and Research (CBER) Regulations that have been published in the first chapter title 21 of the Code of Federal Regulations (CFR). Part 600 of CFR 21 primarily focuses on the established standards like retention samples conditions, temperature to be maintained during shipment, sterilization of equipment, and role and duties of the inspector to inspect the laboratories. The regulation also allows the manufacturer to report any kind of deviation of their product from their intended purpose. Major players in the blood transfusion diagnostics market are BAG Health Care GmbH, Grifols, Bio-Rad Laboratories Inc., Abbott Laboratories, Immucor Inc., Ortho Clinical Diagnostics, DiaSorin S.p.A, Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., and Beckman Coulter Inc. North America was the largest region in the blood transfusion diagnostics market in 2022. Western Europe was the second largest region in the global blood transfusion diagnostics market. The regions covered in global blood transfusion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the blood transfusion diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The blood transfusion diagnostics market consists of revenues earned by entities by providing installation and maintenance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood transfusion diagnostics market also includes sales of blood transfusion diagnostics devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global blood transfusion diagnostics market is segmented - 1) By Type: Instruments and Kits, Reagents, Other Types 2) By End User: Hospitals, Diagnostic Laboratories, Blood Banks, Plasma Fractionation Companies 3) By Technology: Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test 4) By Application: Blood Grouping, Disease Screening